文献速递泌尿男性生殖肿瘤

基线进展类型与治疗中进展事件对mCRPC化疗预后的影响

Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials.
PubMed 文献 · Eur J Cancer · 2019-12-11

该事后分析基于VENICE、TAX327和FIRSTANA三项III期试验数据,评估mCRPC患者一线化疗前基线进展类型及治疗中进展类型对生存的影响。结果显示基线疼痛进展是OS的独立不良预测因素,且治疗中约55%患者疼痛或影像学进展先于PSA进展出现,提示需定期影像学评估而非仅依赖PSA。

要点

  • 基线疼痛进展是mCRPC一线化疗患者OS的独立不良预测因素。
  • 治疗中约55%患者疼痛或影像学进展先于PSA进展出现。
  • 临床不应仅依赖PSA进展,需结合定期影像学评估。

核心结论

  • 基线进展类型强烈预测mCRPC一线化疗患者的总生存期。
  • 治疗中疼痛和/或影像学进展作为首个进展事件先于PSA进展出现于约55%的患者。
  • 该发现有望纳入临床指南并改变实践,提示需定期影像学检查而非仅依赖PSA进展。

研究设计与样本

  • 基于VENICE(n=1224)、TAX327(n=1006)和FIRSTANA(n=1168)三项III期试验的独立数据集进行事后分析。
  • 进展类型分为:仅PSA进展(组1)、影像学(±PSA)进展(组2)、疼痛(±PSA,±影像学)进展(组3)。
  • 采用多因素Cox回归分析(向后剔除法,按ECOG评分和治疗臂分层)评估基线进展类型对OS的影响。

主要发现

  • VENICE中自治疗开始的中位OS(合并臂)在G1、G2、G3分别为28.6、26.3和16.9个月。
  • 与G1相比,G2的HR为1.14(95%CI:0.92-1.41%),G3的HR为2.13(95%CI:1.75-2.59%)。
  • 多因素分析(合并臂)显示基线疼痛进展是OS不良的独立预测因素,TAX327和FIRSTANA数据集观察到类似结果。
  • 治疗期间约55%的患者疼痛或影像学进展先于PSA进展出现。

临床怎么用

  • 对mCRPC一线化疗患者,应关注基线疼痛进展类型以评估预后。
  • 治疗中需定期进行影像学评估,不应仅依赖PSA进展判断疾病进展。

局限性

  • 该研究为回顾性特征分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a discussion about the optimal timing to initiate or switch treatment in metastatic castration-resistant prostate cancer (mCRPC). This post hoc analysis of 3 large trials for men with mCRPC examined the influence of the type of progression at initiation of first-line chemotherapy, as well as the type of progression during treatment, on treatment outcomes. METHODS: Data from the phase III studies VENICE (n = 1224), TAX327 (n = 1006) and FIRSTANA (n = 1168) were used as independent data sets. Type of progression was defined as follows: prostate-specific antigen (PSA) only (group 1), radiological (±PSA) (group 2) or pain (±PSA, ± radiological) progression (group 3). The impact of baseline type of progression on overall survival (OS) was evaluated in multivariate Cox regression analysis with backward elimination, stratified for the Eastern Cooperative Oncology Group performance score and treatment arm. RESULTS: The median OS (arms combined) from treatment initiation in VENICE was 28.6, 26.3 and 16.9 months for G1, G2 and G3, respectively (hazard ratio: 1.14 [95% confidence interval {CI}: 0.92-1.41%] in G2 and 2.13 [95% CI: 1.75-2.59%] in G3 compared with G1). Multivariate analysis (arms combined) showed that pain progression at baseline was an independent predictor of poor OS. Similar findings were observed in the TAX327 and FIRSTANA data sets. During treatment, pain or radiological progression preceded PSA progression in ~55% of the patients. The retrospective characteristic of this study is a limitation. CONCLUSIONS: The type of progression at baseline strongly predicts OS in men with mCRPC treated with first-line chemotherapy. During treatment, pain and/or radiological progression preceded PSA progression as the first progression event in ~55% of the patients. This finding has the prospect to be incorporated in clinical guidelines and to be practice changing because it implies the need for regular imaging and not to rely on PSA progression alone.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Robbrecht DG, Delanoy N, Tannock IF, et al. Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials. Eur J Cancer. 2019. PMID: 31837907. doi:10.1016/j.ejca.2019.10.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。